Skip to main content

Table 3 Summary of in vivo test bed final exam therapy results

From: Deep Bleeder Acoustic Coagulation (DBAC)—part II: in vivo testing of a research prototype system

Test no. Vessel type Depth range Depth of penetration Dosing time (s) Input acoustic power (W) Focal intensitya (W/cm2) Lesionb Vessel occlusionc
1 SFA Shallow 4.7 30 30e 225 472 Y N
2 DFA Deep 11.5 30 378 472 Y N
3 SFA Shallow 5.5 30 30 472 472 N N
4 DFA Shallowd 7.8 30 30 472 472 Y N
5g SFA Shallow 5.2 60 257 472 Y Partial
6 DFA Deep 10.5 60 211 266 Y N
7 SFA Deep 9.2 60 195 266 Y N
8 DFA Deep 11.0 60 218 259 Y N
9 DFA Deep 10.8 18 60 225 266 Y N
10h SFA Shallow 5.2 60 30f 257 472 Y Y
11 DFA Deep 10.7 60 223 266 Y N
12 SFA Shallow 5.6 60 249 486 Y N
  1. Exps 1–4: animal #101; Exps 5–8: animal #104; Exps 9–12: animal #103
  2. aIntensity values are spatial average and temporal average; all foci superposed with attenuation derated according to each respective beam path
  3. bStatus as regards the question: lesion around target region? (targeting assessment)
  4. cOcclusion determined by reduction or stop of flow as evidenced in post-therapy angiography
  5. dAlthough classified as shallow, location was at the border of the shallow-deep transition depth
  6. eProlonged dosing procedure: second dose delivered 27 min after first dose; also one Tx (25 % of aperture) hit array thermal shutoff limits during 30-s dosing
  7. fProlonged dosing procedure: second dose delivered 37 min after first dose
  8. gPartial occlusion animal (#104); skin burns noted with TMM divoting of the PVA
  9. hComplete occlusion animal (#103)